The Journal of Allergy and Clinical Immunology
Volume 113, Issue 5 , Pages 837-844, May 2004

First-aid treatment of anaphylaxis to food: Focus on epinephrine

  • F.Estelle R Simons, MD, FRCPC

      Affiliations

    • Corresponding Author InformationReprint requests: F. Estelle R. Simons, MD, FRCPC, Children's Hospital of Winnipeg, 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9

From the Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health; and the Department of Immunology, National Training Program in Asthma and Allergy, University of Manitoba, Winnipeg, Manitoba, Canada

Received 15 January 2004; received in revised form 15 January 2004; accepted 18 January 2004.

Winnipeg, Manitoba, Canada

Abstract 

Avoiding food triggers for anaphylactic reactions (severe acute systemic allergic reactions) is easier said than done. Most episodes of anaphylaxis to food occur unexpectedly in the community in the absence of a health care professional. All individuals at risk should therefore have an emergency action plan in place. The cornerstone of first-aid treatment of anaphylaxis is epinephrine injected intramuscularly in the vastus lateralis muscle (lateral aspect of the thigh). In this review, we focus on epinephrine. We examine a therapeutic dilemma: the issue of epinephrine dose selection in an individual for whom no optimal fixed-dose auto-injector formulation exists, and a therapeutic controversy: the issue of epinephrine injection versus an oral H1-antihistamine in anaphylaxis episodes that appear to be mild. The pharmaceutical industry could address the first of these issues by providing a wider range of epinephrine fixed doses in easy-to-use auto-injectors, or by providing adjustable epinephrine doses in auto-injectors. The second issue could be addressed in part by development of alternative routes of epinephrine administration for the first-aid, out-of-hospital treatment of anaphylaxis.

Keywords:  Acute allergic reaction, adrenaline, adults, anaphylaxis, auto-injector, children, epinephrine, EpiPen, EpiPen Jr, food allergy, peanut allergy, H1-antihistamines, activated charcoal

Abbreviations:  tmax, Time to peak plasma concentration

 

 Date first published: May 7, 2004; date retracted: May 21, 2004; date republished: May 25, 2004.

PII: S0091-6749(04)00926-1

doi:10.1016/j.jaci.2004.01.769

Refers to erratum:

  • Correction

    The Journal of Allergy and Clinical Immunology June 2004 (Vol. 113, Issue 6, Page 1039)

The Journal of Allergy and Clinical Immunology
Volume 113, Issue 5 , Pages 837-844, May 2004